Pro Dex Inc (PDEX) valuation
Pro Dex P/E ratio history
Pro Dex trades at 16.0 times its earnings over the last twelve months and 18.4 times the earnings analysts expect over the next twelve. At its last 10 fiscal year ends its P/E ranged from 4.9 (year to Jun 2017) to 32.7 (year to Jun 2024), with a median of 13.8.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Jun 30, 2026 | $58.55 | $4.12 | 14.2 | — |
| Jun 30, 2025 | $43.64 | $2.67 | 16.3 | 18.5 |
| Jun 30, 2024 | $19.64 | $0.60 | 32.7 | — |
| Jun 30, 2023 | $19.10 | $1.95 | 9.8 | — |
| Jun 30, 2022 | $15.95 | $1.22 | 13.1 | — |
| Jun 30, 2021 | $30.56 | $1.55 | 19.7 | — |
| Jun 30, 2020 | $17.82 | $1.50 | 11.9 | — |
| Jun 30, 2019 | $12.98 | $0.97 | 13.4 | — |
| Jun 30, 2018 | $6.65 | $0.37 | 18.0 | — |
| Jun 30, 2017 | $6.15 | $1.25 | 4.9 | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Pro Dex valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Pro DexPDEX | $186M | 16.0 | 18.4 | 2.3 |
| InogenINGN | $186M | — | — | 0.5 |
| Upstream BioUPB | $186M | — | — | 58.9 |
| Akebia TherapeuticsAKBA | $190M | — | — | 0.9 |
| Cartesian TherapeuticsRNAC | $191M | — | — | 129.3 |
| Adc Therapeutics SaADCT | $195M | — | — | 2.5 |
| Entrada TherapeuticsTRDA | $176M | — | — | 37.6 |
| OptimizerxOPRX | $175M | 38.8 | 9.7 | 1.8 |
| Sionna TherapeuticsSION | $175M | — | — | — |
| Peer median | 38.8 | 9.7 | 2.5 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: PDEX financials · PDEX returns
No forecast, no recommendation. This page describes Pro Dex Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.